TNYA
Tenaya Therapeutics IncKey Statistics
About Tenaya Therapeutics Inc
Tenaya Therapeutics Inc. is a pioneering clinical-stage biotechnology company focused on transforming the treatment landscape for heart disease through its proprietary engineered heart cell platform. With a robust pipeline of innovative gene therapies and regenerative solutions, Tenaya addresses critical unmet needs in cardiovascular medicine, positioning itself for substantial growth within the biopharmaceutical sector. The company's commitment to scientific rigor and patient-centered outcomes makes it an attractive investment opportunity for institutional investors looking to support the advancement of cardiac care. Tenaya's strategic initiatives reflect its potential to make significant contributions to the evolving market for cardiovascular therapies, highlighting its role as a leader in biomedical innovation.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-84.89M |
| Operating Margin | 0.00% |
| Return on Equity | -83.80% |
| Return on Assets | -43.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.57 |
| Price-to-Book | 1.22 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $217.00M |
| Float | $166.77M |
| % Insiders | 0.47% |
| % Institutions | 50.77% |
Historical Volatility
Volatility is currently expanding